Lantern Pharma's [[LP-184]]: Utilizing their AI platform, RADR®, Lantern Pharma has developed LP-184, a drug candidate that has received Fast Track Designation from the FDA for glioblastoma treatment. LP-184 is currently in Phase 1A clinical trials, showing promise in penetrating the blood-brain barrier and targeting tumor cells effectively.